RO7496353 + atezolizumab

RO7496353 + atezolizumab is an investigational combination therapy consisting of RO7496353, a monoclonal antibody inhibitor targeting transforming growth factor beta 1 (TGF-β1), and atezolizumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1). RO7496353 is designed to neutralize TGF-β1-mediated immunosuppression in the tumor microenvironment, while atezolizumab acts as an immune checkpoint inhibitor by blocking PD-L1 and restoring T-cell mediated antitumor activity[1][3]. This combination is under development for the treatment of advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), and urothelial carcinoma (UC)[1][3][4][9]. The combination is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity in early-phase clinical trials[1][3][4][9].

Other names

RO7496353RO-7496353RO 7496353atezolizumabTecentriq